Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 08, 2012 16:01 ET | Source: Zogenix

Zogenix Reports Second Quarter 2012 Financial Results

Reiterates 2012 Financial Guidance Conference Call and Webcast Today, August 8th, at 4:30 p.m. ET SUMAVEL® DosePro® (sumatriptan injection) Second Quarter 2012 Highlights...
August 01, 2012 08:30 ET | Source: Zogenix

Zogenix Repays Outstanding Loan With Oxford Finance LLC and Silicon Valley Bank

SAN DIEGO, Aug. 1, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
July 31, 2012 07:30 ET | Source: Zogenix

Zogenix Announces Conference Call and Webcast to Present Second Quarter 2012 Financial Results

SAN DIEGO, July 31, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
July 30, 2012 07:30 ET | Source: Zogenix

Zogenix and Battelle Launch "Less is More" DosePro(R) Marketing Campaign

SAN DIEGO and COLUMBUS, Ohio, July 30, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous...
July 24, 2012 09:04 ET | Source: Zogenix

Zogenix Prices Public Offering of Common Stock and Warrants to Purchase Common Stock

SAN DIEGO, July 24, 2012 (GLOBE NEWSWIRE) -- Zogenix Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
July 23, 2012 16:12 ET | Source: Zogenix

Zogenix Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock

SAN DIEGO, July 23, 2012 (GLOBE NEWSWIRE) -- Zogenix Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
July 16, 2012 07:30 ET | Source: Zogenix

Zogenix Announces U.S. Food and Drug Administration (FDA) Acceptance for Review of Zohydro ER(TM) New Drug Application (NDA) for Treatment of Chronic Pain

SAN DIEGO, July 16, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
July 12, 2012 07:30 ET | Source: Zogenix

Zogenix Begins Relday(TM) Clinical Trial for Schizophrenia

Patient Screening and Enrollment Underway With Results Anticipated Before Year-End First-in-Class Needle-Free Once-Monthly Formulation Using DosePro® Delivery System SAN DIEGO, July 12,...
June 07, 2012 07:30 ET | Source: Zogenix

Zogenix and Mallinckrodt, a Covidien Company, Enter Exclusive Co-Promotion Agreement for SUMAVEL(R) DosePro(R)

SAN DIEGO, June 7, 2012 (GLOBE NEWSWIRE) -- Zogenix Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain,...
May 30, 2012 07:30 ET | Source: Zogenix

Zogenix Submits IND for Second DosePro(R) Candidate Relday(TM)

SAN DIEGO, May 30, 2012 (GLOBE NEWSWIRE) -- Zogenix Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain,...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right